Table 18Association between ER status and outcomes

Included TreatmentsAuthor, YearNumber of WomenEstimate/DesignMonths of FollowupER StatusRelative Measure of the Association (95% CI)
Any Recurrence
M, LR, LT, or LKepple, 200638094OR/Observational study48Positive vs. negative1.769 (0.196; 15.953)
M, MR, LRT, LT, LR, or LDawood, 2008351403OR/Observational study60Positive vs. negative12.983 (0.78; 216.181)
Local DCIS or Invasive Carcinoma
LRT, LR, LT, or LProvenzano, 200338195OR/Observational study*101Positive vs. negative0.2 (0.1; 0.8)
L, LR, LT, or LRTRoka, 2004342122OR/Observational study61.6Positive vs. negative0.277 (0.063; 1.222)
LRingberg, 2001379121RR/Observational study*62Positive vs. negative0.5 (0.3; 1.2)
M, LR or Lde Roos, 200733087HR/Observational study*49.8Positive vs. negative0.556 (0.169; 1.667)
LR or LOmlin, 2006312373HR/Observational study*120Positive vs. negative0.71 (0.17; 2.96)
NAWilson, 2006313126OR/Observational study60Positive vs. negative0.738 (0.33; 1.65)
LR or LOmlin, 2006312373HR/Observational study*120Unknown vs. negative0.68 (0.18; 2.59)

Bold = Statistically significant

*

Multivariate analysis

L=Lumpectomy; M=Mastectomy; R=Radiation; T=Tamoxifen

From: 3, Results

Cover of Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)
Diagnosis and Management of Ductal Carcinoma in Situ (DCIS).
Evidence Reports/Technology Assessments, No. 185.
Virnig BA, Shamliyan T, Tuttle TM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.